Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.
On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office. Our team surpassed our goal of raising over $25,000 to fund rare cancer research!
For anyone who follows this blog with even moderate consistency, it is probably clear that Veristat is a growing organization. It is hopefully just as apparent that we are a group who tremendously values and fiercely protects our culture.
Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.